Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for... Key PointsQuestionHow did prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis change in Medicare Part D from 2006 through 2016? FindingsThis cohort study found that between 2006 and 2016, the annual cost of treatment with self-administered disease-modifying therapies for multiple sclerosis more than quadrupled, from a mean of $18 660 to $75 847, increasing at a mean annual rate of 12.8%. Pharmaceutical spending per 1000 beneficiaries increased by 10.2-fold, from $7794 to $79 411, while out-of-pocket spending per 1000 beneficiaries increased by a factor of 7.2, from $372 to $2673. MeaningIn this study, prices of self-administered disease-modifying therapies for multiple sclerosis increased dramatically between 2006 and 2016, which resulted in a 7.2-fold increase in patients’ out-of-pocket costs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D

Loading next page...
 
/lp/american-medical-association/trends-in-prices-market-share-and-spending-on-self-administered-vH3VRRebuD
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2019.2711
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionHow did prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis change in Medicare Part D from 2006 through 2016? FindingsThis cohort study found that between 2006 and 2016, the annual cost of treatment with self-administered disease-modifying therapies for multiple sclerosis more than quadrupled, from a mean of $18 660 to $75 847, increasing at a mean annual rate of 12.8%. Pharmaceutical spending per 1000 beneficiaries increased by 10.2-fold, from $7794 to $79 411, while out-of-pocket spending per 1000 beneficiaries increased by a factor of 7.2, from $372 to $2673. MeaningIn this study, prices of self-administered disease-modifying therapies for multiple sclerosis increased dramatically between 2006 and 2016, which resulted in a 7.2-fold increase in patients’ out-of-pocket costs.

Journal

JAMA NeurologyAmerican Medical Association

Published: Nov 26, 2019

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month